---
title: "Nymox says 20-F is late, citing unfinished work and slow vendor replies"
url: "https://aibio.space/news/nymox-says-20-f-late-citing-unfinished-work-slow-vendor-replies/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-05-01"
section: "Distress"
tickers: "OTC:NYMXF"
source: "https://www.sec.gov/Archives/edgar/data/1018735/000164033425000728/nymox_nt20f.htm"
summary: "The company says it is still compiling required information for its annual report for the year ended December 31, 2024."
---

By the aibio.space news desk.

Sources

- [Nymox Pharmaceutical Corp. NT 20-F (2025-05-01)](https://www.sec.gov/Archives/edgar/data/1018735/000164033425000728/nymox_nt20f.htm)

[NYMXF](https://aibio.space/companies/nymox-pharmaceutical/)

2025-05-01

# Nymox says 20-F is late, citing unfinished work and slow vendor replies to auditors

Tickers [NYMXF](https://aibio.space/companies/nymox-pharmaceutical/)

The company says it is still compiling required information for its annual report for the year ended December 31, 2024.

## Key facts

- **Company**: Nymox Pharmaceutical Corp. (OTC: NYMXF)

- **News type**: Distress

- **Primary source**: [Nymox Pharmaceutical Corp. NT 20-F (2025-05-01)](https://www.sec.gov/Archives/edgar/data/1018735/000164033425000728/nymox_nt20f.htm)

*The Capitol in autumn. CC0, via rawpixel. The picture shows the field, not the companies named.*

Nymox Pharmaceutical Corp. (OTC: [NYMXF](https://aibio.space/companies/nymox-pharmaceutical/)) said on May 1, 2025 that it cannot file its annual report on Form 20-F for the fiscal year ended December 31, 2024 within the prescribed time period without unreasonable effort and expense.

The company filed a Form 12b-25, a notice of late filing that gives a company a short grace period to make the filing.

Nymox says it is still in process of compiling certain required information to complete the Form 20-F, and that some vendors have been delayed in responding to its auditors. As a result, the company requires additional time to prepare and review its consolidated financial statements and other disclosures in the report.

Nymox expects to file the Form 20-F on or before the fifteenth calendar day extension provided by Rule 12b-25.

The company answered no when asked whether it expects a significant change in results of operations from the corresponding period for the last fiscal year. It also said all other periodic reports required during the preceding 12 months have been filed.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

NYMXF

Nymox Pharmaceutical Corp.

OTC · Bahamas

Open the starter desk

## More in Distress

Distress

### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/)

Oct 29, 2026

Distress

### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)

Oct 29, 2026

Distress

### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)

Oct 28, 2026

---
Source page: https://aibio.space/news/nymox-says-20-f-late-citing-unfinished-work-slow-vendor-replies/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Nymox says 20-F is late, citing unfinished work and slow vendor replies", 2025-05-01, https://aibio.space/news/nymox-says-20-f-late-citing-unfinished-work-slow-vendor-replies/